Jorge Ramos

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama et al. · Blood · 2019 · 401 citations · Full text

Life Sciences, Immunology, Oncology +13

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay et al. · Blood · 2019 · 336 citations · Full text

Life Sciences, Immunology, Oncology +14

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Giuseppe Curigliano, Virginia F. Borges, Erika Hamilton et al. · Annals of Oncology · 2021 · 210 citations · Full text

Medicine, Oncology, Pharmacology +17

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

Nancy U. Lin, Rashmi K. Murthy, Vandana G. Abramson et al. · JAMA Oncology · 2022 · 197 citations · Full text

Medicine, Oncology, Pharmacology +17

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa et al. · Journal of Clinical Oncology · 2023 · 100 citations · Full text

Medicine, Oncology, Pharmacology +14